CK Life Sciences International (Holdings), Inc. (HK:0775) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
CK Life Sciences International (Holdings) Inc. reported a sharp 97% decrease in profit attributable to shareholders for the first half of 2024, with no interim dividend declared. Despite setbacks, including COVID-related disruptions, the company is advancing its cancer vaccine, seviprotimut-L, towards a Phase III clinical trial and is developing a non-opioid analgesic, Halneuron®, for cancer pain management, with trials underway in multiple countries.
For further insights into HK:0775 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue